Dan Gruppo, the Vice President of Sales and Marketing for Stryker Upper Trauma and Extremities at Stryker Orthopaedics, Joins CoNextions Medical as Executive Vice President of Sales and Marketing as CoNextions Prepares for its anticipated FDA Clearance and the Launch of its Revolutionary CoNextions TR™ Device in the United States
SANDY, Utah, July 27, 2016 — CoNextions Medical (www.conextionsmed.com) has announced that Dan Gruppo, one of the most experienced and successful sales and marketing executives in Orthopaedics, has joined CoNextions
Medical as Executive Vice President of Global Sales and Marketing beginning August 1st, 2016. Dan was previously the Vice President of Sales and Marketing for Upper Trauma and Extremities at Stryker Orthopaedics. Prior to his last role, Dan held numerous leadership positions at Stryker including Vice President of Sales for Stryker Trauma and Vice President of Marketing for Stryker Trauma and Extremities.
“We are thrilled to announce the hiring of Dan Gruppo, who is one the most accomplished and impressive sales and marketing executives in the orthopedic surgery business,” stated Richard J. Linder, President and Chief Executive Officer and Co-Founder of CoNextions Medical. “Dan shares our passion for excellence in delivering revolutionary products to orthopedic surgery markets with the sole purpose of dramatically improving patient care. As we await regulatory clearance from the US Food and Drug Administration and begin preparations to launch the CoNextions TR™ system, Dan brings a wealth of experience and a specific business acumen necessary to help build our global market strategy and develop a worldwide sales presence that delivers what we believe is a revolutionary technology that could dramatically improve the way patients with soft tissue tendon injuries are treated worldwide.”
Dr. Erik Kubiak, Chief of Orthopedic Trauma Surgery at the University Medical Center in Las Vegas, Nevada and Chairman and Co-Founder of CoNextions Medical stated, “Dan knows physicians around the world and has long worked side by side with orthopedic surgeons to launch new products, train surgeons, and has worked tirelessly to ensure patients receive the best medical technologies and care possible. While Stryker may lose a strategic asset, CoNextions will gain a seasoned and proven executive who fits perfectly into our culture. Dan has launched numerous technologies that have improved patient care across the globe. By adding Dan Gruppo to our executive team, we continue to meet our strategic goal of building CoNextions Medical into a global company with revolutionary new products and technologies to improve patient outcomes and reduce complications.”
Dan Gruppo stated, “It is never easy to leave a large company with a track record of success, such as Stryker, but after meeting the people at CoNextions Medical and seeing the CoNextions TR™ tendon approximation and soft tissue repair system and their future pipeline, it was clear that I had to join the team. The soft tissue repair markets have not seen innovation like the CoNextions TR™ in decades, and certainly nothing comes close to the innovative and easy to use tendon approximation system developed by the remarkable team at CoNextions Medical, Inc. CoNextions brings to the world of orthopedic surgery a very tangible opportunity to improve patient care, something I have sought to accomplish during my career of over 15 years in orthopedic surgery.” Additionally, Dan stated, “The R&D pipeline of products and opportunities at CoNextions Medical, together with the CoNextions TR™, is extremely compelling, and I look forward to August 1st when I join the CoNextions team to participate in commercializing revolutionary products and building a strong global distribution network.”
About CoNextions Medical
Founded in 2011, CoNextions Medical is a privately held company located in Sandy, Utah. They are an innovation-based medical device company dedicated to achieving safer, stronger, and more durable tendon repairs worldwide marked by faster rehabilitation, fewer complications, and lower long-term costs.